Sexual Health in Older Men: ED, Low Testosterone, BPH, and Heart Disease Explained

Why Sexual Health Changes After 50

Sexual function in older men declines through several independent but interacting mechanisms. Testosterone falls, arterial elasticity decreases, prostate tissue enlarges, and chronic diseases accumulate, each one chipping away at a different step of the erection and libido pathway. Understanding which mechanism is driving symptoms is the key to choosing the right treatment rather than the most popular one.

Erectile function depends on nitric-oxide-mediated smooth-muscle relaxation in the corpus cavernosum. That process requires adequate arterial inflow, intact endothelium, sufficient testosterone signaling, and functional pudendal nerve conduction. Age alone degrades all four. Beyond age 60, endothelial nitric oxide synthase activity falls by roughly 30%, arterial compliance drops, and total testosterone typically sits 200 to 300 ng/dL below a man's peak in his 20s. 1

The Massachusetts Male Aging Study (N=1,709) reported a prevalence of complete erectile dysfunction of 5% at age 40, rising to 15% at age 70, with moderate dysfunction adding another 25 percentage points at the older age group. 2 Those numbers mean ED is not an outlier for aging men. It is the statistical norm.

Clinicians now recognize ED as a vascular sentinel event. A man who cannot achieve a firm erection may have impaired penile arterial inflow 3 to 5 years before he has a myocardial infarction. That window is an opportunity, not a reason to withhold treatment.

Erectile Dysfunction: First-Line Treatment and Age-Specific Considerations

PDE5 inhibitors are the standard of care for ED in older men, and age alone does not disqualify anyone from using them. Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) all work by blocking phosphodiesterase type 5, the enzyme that degrades cyclic GMP in penile smooth muscle. More cyclic GMP means better vasodilation during sexual stimulation.

The 2022 AUA/SMSNA guideline states: "Oral PDE5 inhibitors are recommended as first-line therapy for erectile dysfunction in the absence of contraindications." 3 Tadalafil's 36-hour half-life makes it especially practical for older men who may not plan intercourse on a rigid schedule, and its once-daily 5 mg formulation simultaneously treats lower urinary tract symptoms from BPH. 4

Absolute contraindications are narrow. Any concurrent nitrate use (isosorbide mononitrate, nitroglycerin) is a hard stop because the combination produces severe hypotension. Soluble guanylate cyclase stimulators such as riociguat carry the same prohibition. Men on alpha-blockers for BPH or hypertension can use PDE5 inhibitors, but the starting dose should be reduced and timing staggered by at least 4 hours to minimize orthostatic hypotension risk.

For men who do not respond to oral agents, second-line options include intracavernosal alprostadil (Caverject), intraurethral alprostadil (MUSE), and vacuum erection devices. Penile prosthesis implantation is the most effective long-term intervention for refractory ED, with patient satisfaction rates above 90% at 5 years in prospective series. 5

Low Testosterone in Aging Men: When to Test and When to Treat

Testosterone declines at approximately 1 to 2% per year after age 30. That trajectory means a 65-year-old man whose peak testosterone was 750 ng/dL may now measure 450 to 550 ng/dL, a level that is "normal" by most lab reference ranges but meaningfully lower than his personal baseline. Clinical hypogonadism defined as total testosterone below 300 ng/dL affects an estimated 20 to 39% of men over 45. 6

Symptoms worth screening for include reduced libido, morning erection loss, fatigue not explained by sleep apnea or thyroid disease, loss of muscle mass, increased visceral fat, depressed mood, and difficulty concentrating. No single symptom is specific enough to diagnose hypogonadism alone. The Endocrine Society recommends measuring early-morning total testosterone on two separate occasions before initiating TRT. 7

Testosterone replacement therapy is available as intramuscular injections (testosterone cypionate or enanthate, typically 100 to 200 mg every 1 to 2 weeks), transdermal gels (AndroGel 1.62%, Testim, Axiron), subcutaneous pellets (Testopel), and nasal gel (Natesto). Injectable cypionate has the longest real-world use record and the lowest cost. Gels provide more stable serum levels but carry transference risk if skin contact occurs with women or children before the gel dries.

Treatment targets a total testosterone of 400 to 700 ng/dL in most guidelines, avoiding supraphysiologic peaks above 1 to 000 ng/dL that may drive erythrocytosis. Hematocrit should be checked at baseline, at 3 months, and annually. A hematocrit above 54% requires dose reduction or temporary cessation. 7

For men who want to preserve fertility or who prefer not to suppress endogenous production, clomiphene citrate 25 to 50 mg every other day stimulates pituitary LH and FSH release, raising intratesticular testosterone without exogenous androgen. It is used off-label for this purpose and is not FDA-approved as TRT, but several prospective cohorts show meaningful testosterone increases over 3 to 6 months. 8

TRT and Cardiovascular Risk: What the TRAVERSE Trial Settled

Cardiovascular safety was the central concern that suppressed TRT prescribing after 2010 observational studies suggested harm. The question has now been answered with a randomized controlled trial. The TRAVERSE trial enrolled 5,204 men aged 45, 80 with hypogonadism and pre-existing or high-risk cardiovascular disease. Participants were randomized to testosterone gel 1.62% or placebo and followed for a median of 33 months. The primary MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) was 7.0% in the testosterone group versus 7.3% in the placebo group, a result that satisfied the non-inferiority margin. 9

Based on that trial, the FDA updated product labeling for testosterone therapies in 2024, removing language about a general increased risk of major adverse cardiovascular events. The agency noted that atrial fibrillation and pulmonary embolism occurred at slightly higher rates in the testosterone arm (3.5% vs. 2.4% for AF; 0.9% vs. 0.5% for PE), so those risks remain in labeling and deserve discussion before prescribing. 10

For a man with hypogonadism and stable coronary artery disease, TRT is no longer categorically withheld. The clinical conversation now focuses on the AF and PE signal, hematocrit management, and optimizing concurrent cardiac medications rather than on categorical refusal.

Sexual Health in Men With Diabetes

Diabetes is the single strongest modifiable risk factor for ED. Men with type 2 diabetes are approximately 3.5 times more likely to develop ED than men without diabetes, and onset occurs a decade earlier on average. 11 The mechanism is multifactorial: chronic hyperglycemia damages endothelial nitric oxide synthase, promotes advanced glycation end-product deposition in cavernosal smooth muscle, causes peripheral neuropathy in the pudendal nerve, and accelerates atherosclerosis in the internal pudendal arteries.

Glycemic control slows but does not fully reverse diabetic vascular damage. The ACCORD trial showed that intensive glycemic control (target HbA1c <6.0%) over 3.7 years did not significantly improve erectile function scores compared with standard control, suggesting that once structural vascular changes occur, glucose normalization alone is insufficient. 12

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) address two overlapping issues simultaneously. They improve glycemic control and produce substantial weight loss. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). 13 Weight loss of this magnitude reduces visceral adiposity, lowers estradiol-to-testosterone ratio, and has been shown to restore erectile function scores by 3, 5 IIEF points in obese diabetic men in prospective cohort data. 14

Men with diabetes and ED should also be screened for hypogonadism, since low testosterone worsens insulin resistance and further blunts PDE5 inhibitor response. When both conditions coexist, correcting testosterone to the 400 to 700 ng/dL range before reassessing PDE5 inhibitor efficacy is a logical clinical sequence.

Sexual Health in Men With Heart Disease

The cardiac safety of sexual activity is a common concern for men after a myocardial infarction or with stable angina. Sexual intercourse with a familiar partner generates a peak oxygen demand equivalent to walking briskly up two flights of stairs, roughly 3, 5 metabolic equivalents (METs). A man who can achieve 5 METs on a treadmill without symptoms or ischemic changes can generally resume sexual activity without restriction. 15

The Princeton III Consensus (2012) stratifies cardiovascular risk before prescribing PDE5 inhibitors. Low-risk patients (stable, controlled hypertension; asymptomatic with <3 CAD risk factors; mild valvular disease) may start PDE5 inhibitors without further cardiac workup. High-risk patients (unstable angina, uncontrolled hypertension, recent MI within 2 weeks, NYHA Class III, IV heart failure) require cardiac stabilization before sexual activity resumes. 16

ED as a cardiovascular risk marker deserves emphasis. The CONFIRM registry followed 1,519 men with ED and no known CAD. Over a mean 4.8-year follow-up, 57% of those who later had a coronary event had presented with ED first, at an average of 38.8 months before the cardiac diagnosis. 17 An older man presenting with new-onset ED and no obvious cause should receive cardiovascular risk scoring, a fasting lipid panel, and blood pressure measurement as part of the workup, not as an afterthought.

Statin therapy, ACE inhibitors, and beta-blockers each have nuanced effects on sexual function. Statins do not worsen and may modestly improve erectile function through endothelial mechanisms. Beta-blockers, particularly non-selective agents like propranolol, modestly reduce libido and erectile rigidity; carvedilol and nebivolol have more favorable profiles. Thiazide diuretics carry a small but real risk of ED. When a cardiac drug is suspected as the cause, switching within class often resolves the problem without sacrificing cardiovascular control. 18

Benign Prostatic Hyperplasia and Sexual Function

BPH produces lower urinary tract symptoms (LUTS) that include urinary frequency, urgency, nocturia, and weak stream. Those symptoms independently predict worse erectile function scores even after controlling for age, testosterone, and cardiovascular status. A 2003 analysis of 12,815 men in the EpiLUTS study found that moderate-to-severe LUTS nearly doubled the odds of ED (OR 1.97 to 95% CI 1.68, 2.30). 19

Alpha-blockers such as tamsulosin (Flomax) 0.4 mg daily and alfuzosin (Uroxatral) 10 mg daily relax prostate smooth muscle, improving urinary flow without significant impact on erectile function. Silodosin is highly uroselective but causes retrograde ejaculation in roughly 28% of men, which may be unacceptable to sexually active patients. 20

5-alpha reductase inhibitors (5-ARIs), specifically finasteride (Proscar) 5 mg daily and dutasteride (Avodart) 0.5 mg daily, shrink prostate volume by 20 to 30% over 6 to 12 months but carry a meaningful sexual-side-effect profile. The MTOPS trial (N=3,047) reported a 5.7% incidence of new-onset ED with finasteride versus 4.0% with placebo over a 4.5-year follow-up. 21 A small subset of men report persistent sexual dysfunction after stopping 5-ARIs, a condition sometimes called post-finasteride syndrome. The mechanism remains under investigation; men should be counseled about this risk before starting therapy.

Tadalafil 5 mg daily is FDA-approved for both BPH-related LUTS and ED. A 2012 meta-analysis of four randomized controlled trials (N=1,498) found that tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by a mean 3.8 points and improved IIEF erectile function domain scores by 5.9 points versus placebo. 4 For older men with both conditions, once-daily tadalafil is often the most rational single-agent choice.

TRT in Older Men With BPH: Separating Myth From Evidence

A persistent clinical fear is that TRT accelerates prostate growth or triggers prostate cancer. The saturation model, proposed by Abraham Morgentaler and colleagues, holds that androgen receptors in the prostate are maximally stimulated at testosterone levels well below the hypogonadal range, roughly 150 to 200 ng/dL total testosterone. Raising testosterone from 200 to 600 ng/dL does not proportionally increase prostate androgen receptor activation. 22

The TRAVERSE trial specifically tracked prostate events. Prostate cancer was diagnosed in 0.19% of the testosterone group versus 0.18% of the placebo group over 33 months, a difference that was not statistically significant. Prostate biopsy rates were also similar between arms. 9

Men with treated, low-risk prostate cancer who are on active surveillance are no longer categorically excluded from TRT in updated expert opinion, though they require close PSA monitoring every 3 to 6 months and shared decision-making with a urologist. Men with untreated prostate cancer or rising PSA without biopsy remain candidates for urologic evaluation before TRT initiation. The AUA and Endocrine Society both recommend a baseline PSA before starting TRT and repeat measurement at 3 months and annually thereafter. 37

For men with BPH already on tamsulosin or tadalafil, adding TRT does not worsen urinary symptom scores in published prospective data, though prostate volume monitoring with annual ultrasound is reasonable for men with baseline volumes above 40 mL. 23

Lifestyle Modifications That Directly Improve Sexual Function

Pharmacologic treatments work better when built on a foundation of lifestyle change. Obesity, physical inactivity, cigarette smoking, and obstructive sleep apnea each independently reduce erectile function, and each is at least partially reversible.

A randomized trial by Esposito et al. (N=110 obese men with ED) published in JAMA showed that a 2-year Mediterranean-style dietary intervention producing 10% mean body-weight loss restored erectile function in 31% of men in the intervention group versus 5% in the usual-care group (P<0.001). 24 Aerobic exercise at 40 minutes four times weekly improved IIEF scores by a mean 4.5 points in a separate randomized trial of 43 men with ED. 25

Cigarette smoking constricts cavernosal arteries acutely and damages endothelium chronically. Cessation at any age is associated with partial recovery of erectile function within 12 months in observational data. Obstructive sleep apnea causes nocturnal hypoxemia that suppresses testosterone secretion and blunts nocturnal erections. CPAP therapy for 3 months has been shown to raise morning testosterone by a mean 70 to 90 ng/dL and improve IIEF scores by 2, 4 points in men with moderate-to-severe OSA. 26

Alcohol intake above 14 standard drinks per week is associated with a roughly 60% increase in ED odds in cross-sectional data from the Health Professionals Follow-Up Study (N=17,086). Moderate intake (7 or fewer drinks per week) carries no significant association with ED in the same cohort. 27